CNBC's Simon Hobbs and the Options Action traders discuss the stocks they'll be watching next week. » Read More
The final week of July is guaranteed to be one of the busiest of summer. The coming week is packed with potential market movers.
United Therapeutics' Martine Rothblatt says investors with vision should get into her biotech firm now, before it grows to Google-like proportions.
A panel of Food and Drug Administration advisers voted unanimously in favor of Amgen's version of AbbVie's Humira, a biotech drug that raked in nearly $15 billion last year, according to IMS Health. If approved, Amgen's drug would join a new wave of so-called biosimilars, which have the potential to generate billions in savings for U.S. insurers, doctors and...
A number of America's largest companies are slashing funding to the GOP convention, from hundreds of thousands of dollars in 2012 to zero in 2016.
Goldman Sachs chief U.S. equity strategist David Kostin is expecting a pullback and a range-bound market for the next two years.
The U.K.’s Brexit vote sent global markets into a tailspin. But beyond the gloomy scenarios lie a a few short-term upsides, The Fiscal Times reports.
These stocks to buy on a pullback are the least exposed to a potential European economic crisis, according to Morgan Stanley.
Amgen Chairman and CEO Robert Bradway, provides insight to product innovation, the impact from the political cycle and the outlook for M&A.
Discussing the current state of valuation in the markets with Chad Morganlander, Stifel Portfolio Manager, and Jack Ablin, BMO Private Bank Executive VP & Chief Investment Officer.
Amgen said Wednesday that it has seen positive results for the chronic-migraine prevention drug it has been developing with Novartis.
Michael Farr, Farr Miller & Washington, and Kevin Norris, Univest Wealth Management President, discuss their summer market outlooks and give their picks.
Biotech has been at a low year-to-date, but traders believe the sector is going to make a comeback.
The biotech sector has been sliding, but a turnaround could be afoot. Chad Morganlander of Stifel Nicolaus and Craig Johnson of Piper Jaffray discuss with Brian Sullivan.
Amgen is working on a drug to lower the risk of heart attack, reports CNBC's Meg Tirrell.
Nutanix is the biggest tech name on file for an IPO. While investors wait, its co-founder is bulking up a new company — ThoughtSpot.
A rare and previously unknown variation in some people's genes substantially reduces their heart attack risk, the Icelandic researchers said.
Pfizer will buy Anacor Pharmaceuticals in a deal valued at $5.2 billion, for access to Anacor's non-steroidal topical gel to treat eczema.
U.S. stocks closed mixed in below average trade volume Monday, with gains in health care offsetting declines in materials and energy as oil fell.
Biotech stocks dragged on the market Friday, and some "Fast Money" traders contended the pain may not be done.
Three pillars of valuation driving biotech with CNBC's Meg Tirrell while the Fast Money panel discuss biotech as their top trade of the day.